Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2/COVID-19: a primer for cardiologists.
Neth Heart J. 2020 Jul; 28(7-8):366-383.NH

Abstract

In the late autumn of 2019, a new potentially lethal human coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China. The pandemic spread of this zoonotic virus has created a global health emergency and an unprecedented socioeconomic crisis. The severity of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV‑2, is highly variable. Most patients (~85%) develop no or mild symptoms, while others become seriously ill, some succumbing to disease-related complications. In this review, the SARS-CoV‑2 life cycle, its transmission and the clinical and immunological features of COVID-19 are described. In addition, an overview is presented of the virological assays for detecting ongoing SARS-CoV‑2 infections and the serological tests for SARS-CoV-2-specific antibody detection. Also discussed are the different approaches to developing a COVID-19 vaccine and the perspectives of treating COVID-19 with antiviral drugs, immunomodulatory agents and anticoagulants/antithrombotics. Finally, the cardiovascular manifestations of COVID-19 are briefly touched upon. While there is still much to learn about SARS-CoV‑2, the tremendous recent advances in biomedical technology and knowledge and the huge amount of research into COVID-19 raise the hope that a remedy for this disease will soon be found. COVID-19 will nonetheless have a lasting impact on human society.

Authors+Show Affiliations

Laboratory of Experimental Cardiology, Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands. a.a.f.de_vries@lumc.nl.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32671650

Citation

de Vries, A A F.. "SARS-CoV-2/COVID-19: a Primer for Cardiologists." Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, vol. 28, no. 7-8, 2020, pp. 366-383.
de Vries AAF. SARS-CoV-2/COVID-19: a primer for cardiologists. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2020;28(7-8):366-383.
de Vries, A. A. F. (2020). SARS-CoV-2/COVID-19: a primer for cardiologists. Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 28(7-8), 366-383. https://doi.org/10.1007/s12471-020-01475-1
de Vries AAF. SARS-CoV-2/COVID-19: a Primer for Cardiologists. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2020;28(7-8):366-383. PubMed PMID: 32671650.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2/COVID-19: a primer for cardiologists. A1 - de Vries,A A F, PY - 2020/7/17/pubmed PY - 2020/7/17/medline PY - 2020/7/17/entrez KW - Acute respiratory distress syndrome KW - Antiviral drug KW - Coronavirus disease 2019 KW - Pandemic KW - Severe acute respiratory syndrome coronavirus 2 KW - Vaccine SP - 366 EP - 383 JF - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation VL - 28 IS - 7-8 N2 - In the late autumn of 2019, a new potentially lethal human coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China. The pandemic spread of this zoonotic virus has created a global health emergency and an unprecedented socioeconomic crisis. The severity of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV‑2, is highly variable. Most patients (~85%) develop no or mild symptoms, while others become seriously ill, some succumbing to disease-related complications. In this review, the SARS-CoV‑2 life cycle, its transmission and the clinical and immunological features of COVID-19 are described. In addition, an overview is presented of the virological assays for detecting ongoing SARS-CoV‑2 infections and the serological tests for SARS-CoV-2-specific antibody detection. Also discussed are the different approaches to developing a COVID-19 vaccine and the perspectives of treating COVID-19 with antiviral drugs, immunomodulatory agents and anticoagulants/antithrombotics. Finally, the cardiovascular manifestations of COVID-19 are briefly touched upon. While there is still much to learn about SARS-CoV‑2, the tremendous recent advances in biomedical technology and knowledge and the huge amount of research into COVID-19 raise the hope that a remedy for this disease will soon be found. COVID-19 will nonetheless have a lasting impact on human society. SN - 1568-5888 UR - https://www.unboundmedicine.com/medline/citation/32671650/SARS_CoV_2/COVID_19:_a_primer_for_cardiologists_ L2 - https://dx.doi.org/10.1007/s12471-020-01475-1 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.